CoChat
Sign Up
Cited by 1,139Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Neuropsychiatric symptoms in Alzheimer's disease

Open access
Lyketsos, Constantine G., Carrillo, Maria C., Ryan, J. Michael, Khachaturian, Ara S., Trzepacz, Paula, Amatniek, Joan, Cedarbaum, Jesse, Brashear, Robert +1 more·2011·Alzheimer's & Dementia
DOI 10.1016/j.jalz.2011.05.2410PMC PMC3299979
Open this paper in CoChat — free account

Abstract

Neuropsychiatric symptoms (NPS) are core features of Alzheimer's disease and related dementias. Once thought to emerge primarily in people with late‐stage disease, these symptoms are currently known to manifest commonly in very early disease and in prodromal phases, such as mild cognitive impairment. Despite decades of research, reliable treatments for dementia‐associated NPS have not been found, and those that are in widespread use present notable risks for people using these medications. An Alzheimer's Association Research Roundtable was convened in the spring of 2010 to review what is known about NPS in Alzheimer's disease, to discuss classification and underlying neuropathogenesis and vulnerabilities, and to formulate recommendations for new approaches to tailored therapeutics.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2011.05.2410

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • One or more behavioral and psychological symptoms of dementia affect nearly all people with dementia over the course of their illness.

    “One or more symptoms will affect nearly all people with dementia over the course of their illness.2”

    From Assessment and management of behavioral and psychological symptoms of dementia (2015) · cites this paper as [2]

    The Introduction states that almost all people diagnosed with Alzheimer’s disease develop neuropsychiatric symptoms at some stage. The citing sentence extends that claim to nearly all people with dementia, including dementias other than Alzheimer’s disease; the passage does not establish that broader prevalence. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 79

  1. [2]Geda YE Roberts RO Knopman DS Petersen RC Christianson TJ Pankratz VS Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study Arch Gen Psychiatry 2008 65 1193 1198 18838636 PMC2575648
  2. [3]Taragano FE llegri RF Krupitzki H Sarasola DR Serrano CM Lon L Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients J Clin Psychiatry 2009 70 584 592 19323967 PMC2711522
  3. [5]Allegri RF Sarasola D Serrano CM Taragano FE Arizaga RL Butman J Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer’s disease Neuropsychiatr Dis Treat 2006 2 105 110 19412452 PMC2671738
  4. [6]Jeste DV Finkel SI Psychosis of Alzheimer’s disease and related dementias. Diagnostic criteria for a distinct syndrome Am J Geriatr Psychiatry 2000 8 29 34 10648292
  5. [7]Lyketsos CG Olin J Depression in Alzheimer’s disease: overview and treatment Biol Psychiatry 2002 52 243 252 12182930
  6. [8]Lyketsos CG Lee HB Diagnosis and treatment of depression in Alzheimer’s disease: a practical update for the clinician Dement Geriatr Cogn Disord 2004 17 55 64 14564126
  7. [9]Cummings JL The Neuropsychiatric Inventory: assessing psychopathology in dementia patients Neurology 1997 48 5 Suppl 6 S10 S16 9153155
  8. [11]de Medeiros K Robert P Gauthier S Stella F Politis A Leoutsakos J The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia Int Psychogeriatr 2010 22 984 994 20594384 PMC3314709
  9. [12]Sultzer DL Brown CV Mandelkern MA Mahler ME Mendez MF Chen ST Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer’s disease Am J Psychiatry 2003 160 341 349 12562582
  10. [13]Hashimoto H Monserrat L Nguyen P Feil D Harwood D Mandelkern MA Anxiety and regional cortical glucose metabolism in patients with Alzheimer’s disease J Neuropsychiatry Clin Neurosci 2006 18 521 528 17135378
  11. [14]Marshall GA Monserrat L Harwood D Mandelkern MA Cummings JL Sultzer DL Positron emission tomography metabolic correlates of apathy in Alzheimer disease Arch Neurol 2007 64 1015 1020 17620493
  12. [16]Reeves S Brown R Howard R Grasby P Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease Neurology 2009 72 528 534 19204262 PMC2818181
  13. [17]Mega MS Cummings JL O’Connor SM Dinov ID Reback E Felix J Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease Neuropsychiatry Neuropsychol Behav Neurol 2001 14 63 68 11234910
  14. [20]Lyketsos CG Szekely CA Mielke MM Rosenberg PB Zandi PP Developing new treatments for Alzheimer’s disease: the who, what, when, and how of biomarker-guided therapies Int Psychogeriatr 2008 20 871 889 18498669 PMC2688723
  15. [21]Smith GS Kramer E Hermann C Ma Y Dhawan V Chaly T Serotonin modulation of cerebral glucose metabolism in depressed older adults Biol Psychiatry 2009 66 259 266 19368900 PMC2706292
  16. [22]DeMichele-Sweet MA Sweet RA Genetics of psychosis in Alzheimer’s disease: a review J Alzheimers Dis 2010 19 761 780 20157235 PMC2942073
  17. [23]Sweet RA Bennett DA Graft-Radford NR Mayeux R National Institute on Aging Late-Onset Alzheimer’s Disease Family Study Group Assessment and familial aggregation of psychosis in Alzheimer’s disease from the National Institute on Aging Late Onset Alzheimer’s Disease Family Study Brain 2010 133 Pt 4 1155 1162 20147454 PMC2912688
  18. [24]Ramanathan S Glatt SJ Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis Am J Geriatr Psychiatry 2009 17 839 846 19910872
  19. [25]Borroni B Grassi M Constanzi C Zanetti M Archetti S Franzoni S Haplotypes in cathechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease Neurobiol Aging 2007 28 1231 1238 16837108
  20. [26]Craig D Hart DJ Carson R McIlroy SP Passmore AP Psychotic symptoms inAlzheimer’s disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene Neurosci Lett 2004 368 33 36 15342129
  21. [27]Hwang TJ Masterman DL Ortiz F Fairbanks LA Cummings JL Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms Alzheimer Dis Assoc Disord 2004 18 17 21 15195459
  22. [28]Kaufer DI Cummings JL Ketchel P Smith V MacMillan A Shelley T Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory J Neuropsychiatry Clin Neurosci 2000 12 233 239 11001602
  23. [30]Edwards ER Spira AP Barnes DE Yaffe K Neuropsychiatric symptoms in mild cognitive impairment: differences by subtype and progression to dementia Int J Geriatr Psychiatry 2009 24 716 722 19140134 PMC2735341
  24. [31]Moretti DV Frisoni GB Fracassi C Pievani M Geroldi C Binetti G MCI patients’ EEGs show group differences between those who progress and those who do not progress to AD Neurobiol Aging 2011 32 563 571 20022139
  25. [32]Rosenberg PB Mielke MM Appleby B Oh E Leotsakos JM Lyketsos CG Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction Int J Geriatr Psychiatry 2011 26 364 372 20845402 PMC3204866
  26. [33]Visser PJ Verhey FR Boada M Bullock R De Deyn PP Frisoni GB Development of screening guidelines and clinical criteria for pre-dementia Alzheimer’s disease. The DESCRIPA Study Neuroepidemiology 2008 30 254 265 18515975 PMC2821431
  27. [34]Visser PJ Verhey FR Knol DL Scheltens P Wahlund LO Freund-Levi Y Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study Lancet Neurol 2009 8 619 627 19523877
  28. [35]Kohler S van Boxtel MP van Os J Thomas AJ O’Brien JT Jolles J Depressive symptoms and cognitive decline in community-dwelling older adults J Am Geriatr Soc 2010 58 873 879 20374396
  29. [36]Herrmann N Rabheru K Wang J Binder C Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials Am J Geriatr Psychiatry 2005 13 527 534 15956273
  30. [38]Wilcock GK Ballard CG Cooper JA Loft H Memantine for agitation/aggression and psychosis inmoderately severe to severeAlzheimer’s disease: a pooled analysis of 3 studies J Clin Psychiatry 2008 69 341 348 18294023
  31. [39]Brodaty H Ames D Snowdon J Woodward M Kirwan J Clarnette R Risperidone for psychosis of Alzheimer’s disease and mixed dementia: results of a double-blind, placebo-controlled trial Int J Geriatr Psychiatry 2005 20 1153 1157 16315159
  32. [40]Schneider LS Tariot PN Dagerman KS Davis SM Hsiao JK Ismail MS Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease N Engl J Med 2006 355 1525 1538 17035647
  33. [41]Ballard C Hanney ML Theodoulou M Douglas S McShane R Kossakowski K The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial Lancet Neurol 2009 8 151 157 19138567
  34. [43]Gitlin LN Winter L Dennis MP Hodgson N Hauck WW Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention J Am Geriatr Soc 2010 58 1465 1474 20662955 PMC2955191
  35. [44]David R Zeitzer J Friedman L Noda A O’Hara R Robert P Non-pharmacologic management of sleep disturbance in Alzheimer’s disease J Nutr Health Aging 2010 14 203 206 20191254
  36. [45]Lee DR Thomas AJ Sleep in dementia and caregiving–assessment and treatment implications: a review Int Psychogeriatr 2011 23 190 201 20946702
  37. [46]McCurry SM Pike KC Vitiello MV Logsdon RG Teri L Factors associated with concordance and variability of sleep quality in persons with Alzheimer’s disease and their caregivers Sleep 2008 31 741 748 18517044 PMC2398744
  38. [47]Most EI Scheltens P van Someren EJ Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light–a randomized clinical trial Trials 2010 11 19 20178604 PMC2841161
  39. [49]Gehrman PR Connor DJ Martin JL Shochat T Corey-Bloom J Ancoli-Israel S Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease Am J Geriatr Psychiatry 2009 17 166 169 19155748 PMC2630117
  40. [50]Fiorentino L Martin JL Awake at 4 AM: treatment of insomnia with early morning awakenings among older adults J Clin Psychol 2010 66 1161 1174 20845423 PMC3377480
  41. [51]Ownby RL Citalopram versus risperidone for behavioral problems in dementia Curr Psychiatry Rep 2008 10 8 9 18269888
  42. [52]Ballard CG Gauthier S Cummings JL Brodaty H Grossberg GT Robert P Management of agitation and aggression associated with Alzheimer disease Nat Rev Neurol 2009 5 245 255 19488082
  43. [53]Herrmann N Cappell J Eryavec GM Lanctot KL Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer’s disease: an open-label pilot study CNS Drugs 2011 25 425 433 21476613
  44. [54]Olin JT Schneider LS Katz IR Meyers BS Alexopoulos GS Breitner JC Provisional diagnostic criteria for depression of Alzheimer disease Am J Geriatr Psychiatry 2002 10 125 128 11925273
  45. [55]Starkstein SE Ingram L Garau ML Mizrahi R On the overlap between apathy and depression in dementia J Neurol Neurosurg Psychiatry 2005 76 1070 1074 16024880 PMC1739766
  46. [56]Ownby RL Acevedo A Harwood DG Barker WW Duara R Patterns of depression in Spanish- and English-speaking patients with Alzheimer’s disease J Geriatr Psychiatry Neurol 2008 21 47 55 18287170
  47. [57]Lyketsos CG Sheppard JM Steinberg M Tschanz JA Norton MC Steffens DC Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: the Cache County study Int J Geriatr Psychiatry 2001 16 1043 1053 11746650
  48. [58]Nelson JC Delucchi K Schneider LS Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence Am J Geriatr Psychiatry 2008 16 558 567 18591576
  49. [60]Weintraub D Rosenberg PB Drye LT Martin BK Frangakis C Mintzer JE Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes Am J Geriatr Psychiatry 2010 18 332 340 20220589 PMC2849739
  50. [61]Menza M Dobkin RD Marin H Mark MH Gara M Buyske S A controlled trial of antidepressants in patients with Parkinson disease and depression Neurology 2009 72 886 892 19092112 PMC2677475
  51. [62]Barone P Poewe W Albrecht S Debieuvre C Massey D Rascol O Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial Lancet Neurol 2010 9 573 580 20452823
  52. [63]Zubenko GS Moossy J Kopp U Neurochemical correlates of major depression in primary dementia Arch Neurol 1990 47 209 214 1689144
  53. [64]Meynen G Unmehopa UA Hofman MA Swaab DF Hoogendijk WJ Relation between corticotropin-releasing hormone neuron number in the hypothalamic paraventricular nucleus and depressive state in Alzheimer’s disease Neuroendocrinology 2007 85 37 44 17351315
  54. [65]Steffens DC Payne ME Greenberg DL Byrum CE Welsh-Bohmer KA Wagner HR Hippocampal volume and incident dementia in geriatric depression Am J Geriatr Psychiatry 2002 10 62 71 11790636
  55. [66]Ballard CG Eastwood C Gahir M Wilcock G A follow up study of depression in the carers of dementia sufferers Br Med J 1996 312 947 8616308 PMC2350802
  56. [67]Ballard C Holmes C McKeith I Neill D O’Brien J Cairns N Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease Am J Psychiatry 1999 156 1039 1045 10401449
  57. [68]Ballard CG Margallo-Lana M Fossey J Reichelt K Myint P Potkins D A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments J Clin Psychiatry 2001 62 631 636 11561936
  58. [69]Mega MS Cummings JL Fiorello T Gornbein J The spectrum of behavioral changes in Alzheimer’s disease Neurology 1996 46 130 135 8559361
  59. [70]Robert P Onyike CU Leentjens AF Dujardin K Aalten P Starkstein S Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders Eur Psychiatry 2009 24 98 104 19201579
  60. [71]Jonsson M Edman A Lind K Rolstad S Sjogren M Wallin A Apathy is a prominent neuropsychiatric feature of radiological white-matter changes in patients with dementia Int J Geriatr Psychiatry 2010 25 588 595 19852002
  61. [72]Nakaaki S Murata Y Sato J Shinagawa Y Hongo J Tatsumi H Association between apathy/depression and executive function in patients with Alzheimer’s disease Int Psychogeriatr 2008 20 964 975 18462557
  62. [73]McPherson S Fairbanks L Tiken S Cummings JL Back-Madruga C Apathy and executive function in Alzheimer’s disease J Int Neuropsychol Soc 2002 8 373 381 11939696
  63. [74]Gauthier S Feldman H Hecker J Vellas B Ames D Subbiah P Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease Int Psychogeriatr 2002 14 389 404 12670060
  64. [75]Maletta GJ Winegarden T Reversal of anorexia by methylphenidate in apathetic, severely demented nursing home patients Am J Geriatr Psychiatry 1993 1 10 28530924
  65. [76]Galynker I Ieronimo C Miner C Rosenblum J Vilkas N Rosenthal R Methylphenidate treatment of negative symptoms in patients with dementia J Neuropsychiatry Clin Neurosci 1997 9 231 239 9144102
  66. [77]Jansen IH Olde Rikkert MG Hulsbos HA Hoefnagels WH Toward individualized evidence-based medicine: five “N of 1” trials of methylphenidate in geriatric patients J Am Geriatr Soc 2001 49 474 476 11347795
  67. [78]Padala PR Burke WJ Bhatia SC Petty F Treatment of apathy with methylphenidate J Neuropsychiatry Clin Neurosci 2007 19 81 83 17308232
  68. [79]Padala PR Burke WJ Shostrom VK Bhatia SC Wengel SP Potter JF Methylphenidate for apathy and functional status in dementia of the Alzheimer type Am J Geriatr Psychiatry 2010 18 371 374 20220576
  69. [80]Herrmann N Rothenburg LS Black SE Ryan M Liu BA Busto UE Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge J Clin Psychopharmacol 2008 28 296 301 18480686
  70. [81]Mitchell RA Herrmann N Lanctot KL The role of dopamine in symptoms and treatment of apathy in Alzheimer’s disease CNS Neurosci Ther (in press) PMC6493833 20560994
  71. [83]Tunnard C Whitehead D Hurt C Wahlund LO Mecocci P Tsolaki M Apathy and cortical atrophy in Alzheimer’s disease Int J Geriatr Psychiatry 2011 26 741 748 20872914
  72. [85]Starkstein SE Mizrahi R Capizzano AA Acion L Brockman S Power BD Neuroimaging correlates of apathy and depression in Alzheimer’s disease J Neuropsychiatry Clin Neurosci 2009 21 259 265 19776304
  73. [86]Lanctot KL Herrmann N Black SE Ryan M Rothenburg LS Liu BA Apathy associated with Alzheimer disease: use of dextroamphetamine challenge Am J Geriatr Psychiatry 2008 16 551 557 18591575
  74. [87]Lyketsos CG Rosenblatt A Rabins P Forgotten frontal lobe syndrome or “Executive Dysfunction Syndrome” Psychosomatics 2004 45 247 255 15123852
  75. [88]Drayton SJ Davies K Steinberg M Leroi I Rosenblatt A Lyketsos CG Amantadine for executive dysfunction syndrome in patients with dementia Psychosomatics 2004 45 205 209 15123844
  76. [89]Kertesz A Nadkarni N Davidson W Thomas AW The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia J Int Neuropsychol Soc 2000 6 460 468 10902415
  77. [90]Imamura T Takanashi M Hattori N Fujimori M Yamashita H Ishii K Bromocriptine treatment for perseveration in demented patients Alzheimer Dis Assoc Disord 1998 12 109 113 9651140
  78. [91]Kraus MF Maki PM Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review J Neuropsychiatry Clin Neurosci 1997 9 222 230 9144101
  79. [92]Laughren T A regulatory perspective on psychiatric syndromes in Alzheimer disease Am J Geriatr Psychiatry 2001 9 340 345 11739061

Cited by

Sorted by citations

Authors
Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., Khachaturian, A. S., Trzepacz, P., Amatniek, J., Cedarbaum, J., Brashear, R., & Miller, D. S.
Affiliations
  • Johns Hopkins University (US)
  • Alzheimer's Association Chicago IL USA
  • Pfizer (United States) (US)
  • Khachaturian and Associates Washington DC USA
  • Eli Lilly (United States) (US)
  • Princeton University (US)
  • Elan Corporation South San Francisco CA USA
  • Janssen (United States) (US)
  • United BioSource Corporation Wayne PA USA
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2011-09
Volume
7
Issue
5
Pages
532-539
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1016/j.jalz.2011.05.2410
PMC
PMC3299979
OpenAlex
W2108335346
Cited by
1,139
References
9
Citations by year
2026: 85 · 2025: 111 · 2024: 132 · 2023: 121 · 2022: 130 · 2021: 111 · 2020: 83 · 2019: 67 · 2018: 66 · 2017: 60 · 2016: 50 · 2015: 43 · 2014: 31 · 2013: 35 · 2012: 9
FWCI
17.17
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
Johns Hopkins Alzheimer's Disease Research Center (P50AG005146)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
neuropsychiatric symptoms, Alzheimer's disease
MeSH terms
Aged, Aggression, Alzheimer Disease, Consensus Development Conferences as Topic, Consensus Statements as Topic, Depressive Disorder, Humans, Neurocognitive Disorders, Apathy, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review